ViiV Healthcare's Lotivibart HIV Treatment Shows Positive Phase IIb Data
Analysis based on 7 articles · First reported Feb 25, 2026 · Last updated Feb 27, 2026
The positive clinical trial results for lotivibart are expected to positively impact the pharmaceutical market, particularly in the HIV treatment sector. This breakthrough could lead to new long-acting treatment options, benefiting patients and potentially increasing the market share for GSK===ViiV Healthcare and its parent company, GSK.
GSK===ViiV Healthcare, majority-owned by GSK with Pfizer and Shionogi as shareholders, announced positive 12-month interim efficacy and tolerability data from its phase IIb EMBRACE study. The study evaluated lotivibart (N6LS), a broadly neutralizing antibody, combined with monthly intramuscular long-acting cabotegravir (CAB LA) for adults living with HIV. The regimen maintained viral suppression in 94% of participants receiving lotivibart intravenously and 82% subcutaneously, compared to 88% in the standard of care group. These favorable results reinforce lotivibart's ultra long-acting potential, with dosing every four months or longer, and support the progression of the study to evaluate a twice-yearly intravenous dosing interval. The findings were presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, Colorado. This development builds on previous six-month data and signifies a potential advancement in HIV treatment options.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard